Hospira Reports Third-Quarter 20...(Integration-related charges (C) 2....),Health

Date:10/27/2009

Integration-related charges (C) 2.8 5.4 4.5 0.03 --------- ---------- ------ ------- Adjusted financial measures $355.5 $161.5 $101.5 $0.63 ========= ========== ====== ======= GAAP results for the three months ended September 30, 2008 include: A -- Facilities Optimization charges: $3.7 million reported in Cost of products sold and $4.5 million reported in Restructuring and impairment. These charges relate to facilities optimization from the closure or departure from certain manufacturing and R&D facilities and include costs for severance and other employee benefits, accelerated depreciation and relocation of production and R&D operations. B -- Amortization of Mayne Pharma intangible assets is reported in Cost of products sold. C -- Integration-related charges: $2.8 million reported in Cost of products sold, $0.2 million reported in Research and development and $2.4 million reported in Selling, general and administrative. These charges relate to the integration of Mayne Pharma and other acquisitions into our operations and include costs for closure of facilities, termination of lease agreements, severance and other employee benefit costs. (1) Gross profit is defined as Net sales less Cost of products sold. Hospira, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) (dollars and shares in millions, except for per share amounts) The Non-GAAP financial measures contained in this press release (including adjusted gross profit, adjusted income from operations, adjusted net income, and adjusted diluted Earnings Per Share) adjust for certain spe
'/>"/>

SOURCE Hospira, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Related medicine technology :

1. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
2. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA
3. Hospira, Celltrion, Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs
4. Hospira to Present at Credit Suisse 18th Annual Healthcare Conference Nov. 11
5. Hospira Names Daphne E. Jones Chief Information Officer
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Spherix Reports Second Quarter Earnings
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs